NEW YORK (GenomeWeb) – Having refined its platform and manufacturing process, diagnostics firm HealthTell has now moved into clinical feasibility studies with the aim of launching its first test by the end of next year, CEO Bill Colston told ProteoMonitor this week.

Launched in 2010 as a spinout from Arizona State University's Biodesign Institute, San Ramon, Calif.-based HealthTell aims to commercialize diagnostics based on the immunosignaturing technology developed by Biodesign researchers, and company co-founders Stephen Johnston, Neal Woodbury, and John Rajasekaran.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

In Science this week: analysis of DNA from ancient North Africans, and more.